ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Carboplatin

Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.

Drug pageCarboplatin: every studyMany companies study it; this page follows only the 89 they lead. All 1,229 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 24, 200989 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only300 open or runningphase 4since Nov 24, 2009Apr 30, 2002none ahead
Bristol-Myers Squibbits history only140 open or runningphase 4since May 28, 2014Sep 13, 2001none ahead
Sanofiits history only70 open or runningphase 3since Jul 11, 2001Jul 11, 2001none ahead
Sarah Cannon Research Instituteits history only31 open or runningphase 2since Nov 2, 2005Nov 2, 2005none ahead
Swedish Orphan Biovitrumits history only30 open or runningphase 3since Feb 5, 2003Feb 5, 2003none ahead
AGO Researchits history only20 open or runningphase 3since Apr 16, 2013Apr 16, 2013none ahead
CarTheraits history only21 open or runningphase 3since Jun 5, 2023Nov 13, 2018Jan 28, 2028phase 3 · NCT05902169
Eisaiits history only20 open or runningphase 3since Dec 31, 2002Dec 31, 2002none ahead
InSightecits history only20 open or runningphase 2since Jun 1, 2020Jun 1, 2020none ahead
Ionis Pharmaceuticalsits history only20 open or runningphase 3since Jun 6, 2001Jun 6, 2001none ahead
Johnson & Johnson21 open or runningphase 3since Aug 31, 2020Jun 12, 2008none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Daiichi Sankyo, AstraZeneca, Merck, Parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, Novotech (Australia) Pty, WuXi CDS Clinical Research (Shanghai), Valerio Therapeutics, Ortho Biotech, Tibotec Pharmaceutical and Medarex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2008First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT00698451 · 54 enrolled · United States
  2. Aug 31, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04538664 · 308 enrolled · United States, Australia, Belgium and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more3Active, not recruitingMay 3, 2023308
NCT00698451Ovarian Neoplasms · United States2CompletedOct 201054

How it is read

Names in the registry

  • “Carboplatin”, 110 entries
  • “carboplatin”, 38 entries
  • “Pemetrexed/Carboplatin”, 2 entries
  • “CARBOPLATIN”, 2 entries
  • “Carboplatin/Paclitaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.